Therapeutic delivery of proteins to macrophages: Implications for treatment of Gaucher's disease

被引:76
作者
Mistry, PK
Wraight, EP
Cox, TM
机构
[1] UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND
[2] ADDENBROOKES HOSP TRUST,DEPT NUCL MED,CAMBRIDGE,ENGLAND
关键词
D O I
10.1016/S0140-6736(96)04451-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The primary defect in Gaucher's disease, a lysosomal disorder affecting macrophages, is in the activity of glucocerebrosidase. Treatment with exogenous enzyme (modified to increase its affinity for macrophage glycoprotein receptors) aims to restore this activity. However, the fate of the exogenous enzyme in vivo is unknown. We used radiolabelled enzyme to assess macrophage receptor activity for mannosylated ligands in vivo. Methods We examined the uptake and tissue distribution of radiolabelled enzyme molecules by gamma scintigraphy after bolus injection of iodine-123-labelled recombinant or placental enzyme (imiglucerase and alglucerase, respectively) in eight patients with type 1 Gaucher's disease, and in one healthy individual. The metabolism of the tracer enzyme was followed by scintigraphy and by analysis of blood, urine, and faeces. Results The tracer enzyme was rapidly cleared from blood (half-life 4.7 min [SD 1.0]). Concomitantly, there was avid uptake by the liver (about 30% of the injected dose), the spleen (about 15%), and the bone marrow. 40-55% of the tracer was cleared rapidly from the viscera (half-life 1-2 h) and 45-60% was cleared slowly (half-life 34-42 h). The half-life in the bone marrow was 14.1 h. Infusion of alglucerase at dose of 5 U/kg bodyweight normalised acid beta-glucosidase activity of splenic Gaucher's cells in vivo. When the enzyme was administered at a seven-fold higher dose (35 U/kg over 1 h), the receptor-mediated uptake in vivo was saturated, as shown by the increase in blood-clearance half-life of tracer enzyme from 4.5 min to 12 min. Interpretation Avid and saturable uptake of modified glucocerebrosidase was found, which indicates high-affinity targeting to the macrophage system in vivo. The rate of enzyme turnover suggests a rational basis for use of this therapy in treatment of Gaucher's disease.
引用
收藏
页码:1555 / 1559
页数:5
相关论文
共 32 条
[1]   HUMAN BETA-GLUCURONIDASE - INVIVO CLEARANCE AND INVITRO UPTAKE BY A GLYCOPROTEIN RECOGNITION SYSTEM ON RETICULOENDOTHELIAL CELLS [J].
ACHORD, DT ;
BROT, FE ;
BELL, CE ;
SLY, WS .
CELL, 1978, 15 (01) :269-278
[2]  
BARTON NW, 1993, NEW ENGL J MED, V328, P1564
[3]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DIBISCEGLIE, AM ;
DOPPELT, SH ;
HILL, SC ;
MANKIN, HJ ;
MURRAY, GJ ;
PARKER, RI ;
ARGOFF, CE ;
GREWAL, RP ;
YU, KT .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470
[4]   FAILURE OF ALGLUCERASE INFUSED INTO GAUCHER DISEASE PATIENTS TO LOCALIZE IN MARROW MACROPHAGES [J].
BEUTLER, E ;
KUHL, W ;
VAUGHAN, LM .
MOLECULAR MEDICINE, 1995, 1 (03) :320-324
[5]  
Beutler E., 1995, METABOLIC MOL BASES, P2641
[6]   Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase - Predominant uptake by liver endothelial cells [J].
Bijsterbosch, MK ;
Donker, W ;
VandeBilt, H ;
VanWeely, S ;
VanBerkel, TJC ;
Aerts, JMFG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 237 (02) :344-349
[7]   LABELING OF PROTEINS TO HIGH SPECIFIC RADIOACTIVITIES BY CONJUGATION TO A I-125-CONTAINING ACYLATING AGENT - APPLICATION TO RADIOIMMUNOASSAY [J].
BOLTON, AE ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1973, 133 (03) :529-538
[8]   ENZYME REPLACEMENT THERAPY FOR GAUCHER DISEASE - CRITICAL INVESTIGATIONS BEYOND DEMONSTRATION OF CLINICAL EFFICACY [J].
BRADY, RO ;
BARTON, NW .
BIOCHEMICAL MEDICINE AND METABOLIC BIOLOGY, 1994, 52 (01) :1-9
[9]   SURFACE MARKER AND OTHER CHARACTERISTICS OF GAUCHERS CELLS [J].
BURNS, GF ;
CAWLEY, JC ;
FLEMANS, RJ ;
HIGGY, KE ;
WORMAN, CP ;
BARKER, CR ;
ROBERTS, BE ;
HAYHOE, FGJ .
JOURNAL OF CLINICAL PATHOLOGY, 1977, 30 (10) :981-988
[10]   HCG CONTAMINATION OF ALGLUCERASE - CLINICAL IMPLICATIONS IN LOW-DOSE REGIMEN [J].
COHEN, Y ;
ELSTEIN, D ;
ABRAHAMOV, A ;
HIRSCH, H ;
ZIMRAN, A .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (03) :235-236